Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03326102
Study type Interventional
Source Daehwa Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 2
Start date July 6, 2018
Completion date December 13, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03947736 - Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
Completed NCT03109249 - Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer Phase 1
Active, not recruiting NCT03315364 - Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy Phase 2/Phase 3